收稿日期: 2022-03-20
网络出版日期: 2022-11-07
赵含丹, 许利军 . 人类免疫缺陷病毒相关隐球菌脑膜炎的诊治现状和挑战[J]. 诊断学理论与实践, 2022 , 21(04) : 419 -424 . DOI: 10.16150/j.1671-2870.2022.04.001
| [1] | Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy[J]. Nat Rev Neurol, 2017, 13(1):13-24. |
| [2] | 中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病, 2021, 27(11):1182-1201. |
| [2] | AIDS and hepatitis C group, infectious diseases branch, Chinese Medical Association, China Center for Disease Control and prevention. China AIDS diagnosis and treatment guide(2021 Edition)[J]. Chin J AIDS & STD, 2021, 27(11):1182-1201. |
| [3] | Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options[J]. Clin Epidemiol, 2014, 6:169-182. |
| [4] | Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. AIDS, 2009, 23(4):525-530. |
| [5] | Jarvis JN, Tenforde MW, Lechiile K, et al. Evaluation of a novel semiquantitative cryptococcal antigen lateral flow assay in patients with advanced HIV disease[J]. J Clin Microbiol, 2020, 58(9):e00441-20. |
| [6] | Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis[J]. Lancet Infect Dis, 2017, 17(8):873-881. |
| [7] | Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection[J]. Cell Mol Neurobiol, 2005, 25(1):181-199. |
| [8] | Kanmogne GD, Schall K, Leibhart J, et al. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis[J]. J Cereb Blood Flow Metab, 2007, 27(1):123-134. |
| [9] | Maziarz EK, Perfect JR. Cryptococcosis[J]. Infect Dis Clin North Am, 2016, 30(1):179-206. |
| [10] | Zhao H, Zhou M, Zheng Q, et al. Clinical features and outcomes of cryptococcemia patients with and without HIV infection[J]. Mycoses, 2021, 64(6):656-667. |
| [11] | Wake RM, Britz E, Sriruttan C, et al. High cryptococcal antigen titers in blood are predictive of subclinical cryptococcal meningitis among human immunodeficiency virus-infected patients[J]. Clin Infect Dis, 2018, 66(5):686-692. |
| [12] | Robertson EJ, Najjuka G, Rolfes MA, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis[J]. J Infect Dis, 2014, 209(1):74-82. |
| [13] | Antinori S. New Insights into HIV/AIDS-Associated Cryptococcosis[J]. ISRN AIDS, 2013, 2013:471363. |
| [14] | Xu L, Xu Y, Zheng Y, et al. Differences in cytokine and chemokine profiles in cerebrospinal fluid caused by the etiology of cryptococcal meningitis and tuberculous meningitis in HIV patients[J]. Clin Exp Immunol, 2021, 206(1):82-90. |
| [15] | Xu L, Guo Y, Zhao Y, et al. Chemokine and Cytokine cascade caused by skewing of the Th1-Th2 balance is associated with high intracranial pressure in HIV-associa-ted cryptococcal meningitis[J]. Mediators Inflamm, 2019, 2019:2053958. |
| [16] | Jiang YK, Wang RY, Zhou LH, et al. Cerebrospinal fluid cytokine and chemokine patterns correlate with prognosis of HIV-uninfected cryptococcal meningitis: A prospective observational study[J]. Front Immunol, 2022, 13:993495. |
| [17] | 刘正印, 王贵强, 朱利平, 等. 隐球菌性脑膜炎诊治专家共识[J]. 中华内科杂志, 2018, 57(5):317-323. |
| [17] | Liu ZY, Wang GQ, Zhu LP, et al. Expert consensus on the diagnosis and treatment of cryptococcal meningitis[J]. Chin J Intern Med, 2018, 57(5):317-323. |
| [18] | Xu L, Yu J, Zheng B, et al. HIV infection does not increase 10-week mortality of Chinese cryptococcal meningitis patients[J]. AIDS Res Hum Retroviruses, 2020, 36(9):734-741. |
| [19] | Rajasingham R, Wake RM, Beyene T, et al. Cryptococcal Meningitis diagnostics and screening in the era of point-of-care laboratory testing[J]. J Clin Microbiol, 2019, 57(1):e01238-18. |
| [20] | Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast[J]. Emerg Infect Dis, 2014, 20(1):45-53. |
| [21] | 潘孝彰, 卢洪洲, 沈银忠. 冀望病原微生物的诊断有更大发展[J]. 诊断学理论与实践, 2010, 9(6):541-544. |
| [21] | Pan XZ, Lu HZ, Shen YZ. Prospects on advances in diagnosis of pathogenic microorganisms[J]. J Diagn Concepts & Pract, 2010, 9(6):541-544. |
| [22] | “十三五”国家科技重大专项艾滋病机会性感染课题组. 艾滋病合并隐球菌病临床诊疗的专家共识[J]. 西南大学学报(自然科学版), 2020, 42(7):1-19. |
| [22] | AIDS-Associated Opportunistic Infections Research Group of the National Science and Technology Marjor Project of China During the 13th Fiver-Year Plan Period. Expert consensus on the diagnosis and treatment of cryptococcosis in AIDS patients[J]. J Southwest Univ(Nat Sci), 2020, 42(7):1-19. |
| [23] | Tang MW, Clemons KV, Katzenstein DA, et al. The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time[J]. Crit Rev Microbiol, 2016, 42(4):634-642. |
| [24] | Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: What do we know now[J]. Fungal Genet Biol, 2015, 78:49-54. |
| [25] | Gushiken AC, Saharia KK, Baddley JW. Cryptococcosis[J]. Infect Dis Clin North Am, 2021, 35(2):493-514. |
| [26] | Wilson MR, Sample HA, Zorn KC, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis[J]. N Engl J Med, 2019, 380(24):2327-2340. |
| [27] | Chiu CY, Miller SA. Clinical metagenomics[J]. Nat Rev Genet, 2019, 20(6):341-355. |
| [28] | Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection[J]. Annu Rev Pathol, 2019, 14:319-338. |
| [29] | WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for The Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection[M]. Geneva: World Health Organization, 2018. |
| [30] | Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2010, 50(3):291-322. |
| [31] | Jarvis JN, Lawrence DS, Meya DB, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis[J]. N Engl J Med, 2022, 386(12):1109-1120. |
| [32] | Temfack E, Boyer-Chammard T, Lawrence D, et al. New insights into cryptococcus spp. biology and cryptococcal meningitis[J]. Curr Neurol Neurosci Rep, 2019, 19(10):81. |
| [33] | WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease Among Adults, Adolescents and Children Living with HIV[M]. Geneva: World Health Organization, 2022. |
| [34] | Xu L, Tao R, Wu J, et al. Short-course rather than low-dose amphotericin B may exert potential influence on mortality in cryptococcal meningitis patients treated with amphotericin B plus flucytosine alone or in combination with fluconazole[J]. Front Microbiol, 2019, 10:2082. |
| [35] | Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes[J]. Clin Infect Dis, 2014, 58(5):736-745. |
| [36] | Zhou Y, Yang Z, Liu M, et al. Independent risk factors for deaths due to AIDS in Chongqing, China: Does age matter?[J]. Front Med (Lausanne), 2021, 7:586390. |
| [37] | Wu L, Xiao J, Song Y, et al. The clinical characteristics and outcome of cryptococcal meningitis with AIDS in a tertiary hospital in China: an observational cohort study[J]. BMC Infect Dis, 2020, 20(1):912. |
| [38] | Chen J, Zhang R, Shen Y, et al. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis[J]. HIV Med, 2019, 20(1):69-73. |
| [39] | Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi[J]. Clin Infect Dis, 2010, 50(3):338-344. |
| [40] | Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis[J]. AIDS, 2007, 21(16):2119-2129. |
| [41] | Yao Y, Zhang JT, Yan B, et al. Voriconazole: a novel treatment option for cryptococcal meningitis[J]. Infect Dis(Lond), 2015, 47(10):694-700. |
| [42] | Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole[J]. Clin Pharmacokinet, 2006, 45(7):649-663. |
| [43] | 陶然, 师金川, 郭永征, 等. 两性霉素B去氧胆酸盐、两性霉素B脂质体和伏立康唑诱导治疗HIV相关性隐球菌脑膜炎的效果比较[J]. 新发传染病电子杂志, 2019, 4(2):97-102. |
| [43] | Tao R, Shi JC, Guo YZ, et al. Comparison of amphotericin B deoxycholate, amphotericin B liposome and voriconazole as induction treatment on HIV-related cryptococcal meningitis[J]. Electron J Emerg Infect Dis, 2019, 4(2):97-102. |
| [44] | Murphy RA, Hatlen TJ, Moosa MS. High-dose fluconazole consolidation therapy for cryptococcal meningitis in sub-saharan Africa: much to gain, little to lose[J]. AIDS Res Hum Retroviruses, 2018, 34(5):399-403. |
| [45] | Rolfes MA, Rhein J, Schutz C, et al. Cerebrospinal fluid culture positivity and clinical outcomes after amphotericin-based induction therapy for cryptococcal meningitis[J]. Open Forum Infect Dis, 2015, 2(4):ofv157. |
| [46] | Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial[J]. Lancet Infect Dis, 2014, 14(4):281-290. |
| [47] | Tao R, Xu L, Guo Y, et al. Ventriculoperitoneal shunt is associated with increased cerebrospinal fluid protein level in HIV-infected cryptococcal meningitis patients[J]. BMC Infect Dis, 2022, 22(1):286. |
| [48] | Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related cryptococcus neoformans disease in the era of highly active antiretroviral therapy[J]. Clin Infect Dis, 2005, 40(7):1049-1052. |
| [49] | Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis[J]. N Engl J Med, 2014, 370(26):2487-2498. |
| [50] | Tao R, Peng X, Liu X, et al. Outcome of lenalidomide treatment for cognitive impairment caused by immune reconstitution inflammatory syndrome in patients with HIV-related cryptococcal meningitis[J]. J Inflamm Res, 2022, 15:5327-5336. |
/
| 〈 |
|
〉 |
